Imatinib blocks many protein kinases, including fusion proteins BCR-ABL and KIT, and has been approved for the treatment of chronic myelogenous leukaemia and gastrointestinal stromal tumours. Here, BCR is linked to chronic myelogenous leukemia, BCR-ABL1 positive.